Lyka Labs Ltd.
Snapshot View

View in App

Prices View details >>

117.20 -0.55 ▼-0.5%

17 August 2022, 10:19:55 AM
Volume: 10,698

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lykalabs.com
Market Cap 337.54 Cr.
Enterprise Value(EV) 450.92 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 6.99 Trailing Twelve Months Ending 2022-06
Price-Earning Ratio (PE) 16.88 Trailing Twelve Months Ending 2022-06
Industry PE 32.22 Trailing Twelve Months Ending 2022-06
Book Value / Share 4.90 Trailing Twelve Months Ending 2022-06
Price to Book Value 24.09 Calculated using Price: 117.95
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 2.87 Cr. 28,690,000 Shares
FaceValue 10
Company Profile
Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on December 19, 1985.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.47%
1 Week
-1.26%
1 Month
-10.98%
3 Month
-17.03%
6 Month
-19.42%
1 Year
+46.78%
2 Year
+484.54%
5 Year
+112.32%
10 Year
+1077.89%

Ratios View Details >>

9 years 2014-06 2015-06 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) -11.06 -13.05 11.74 -18.27 -46.30 -14.20 -448.65
Return on Capital Employed (%) 11.93 11.73 12.41 6.66 -6.52 -5.50 -31.39 8.95 56.68
Return on Assets (%) -1.72 -1.55 1.58 -2.70 -8.02 -2.97 -32.05 -5.58 21.40

Balance Sheet View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 67 53 43 45 38 49 43 -14 -26 13
Non Curr. Liab. 72 65 37 29 39 5 72 137 149 73
Curr. Liab. 147 208 195 163 165 167 85 66 50 99
Minority Int. 3 3 4 4 7 3 3 -1 1 0
Equity & Liab. 289 329 279 241 249 225 203 188 174 186
Non Curr. Assets 162 211 177 159 186 176 168 152 145 133
Curr. Assets 127 118 102 82 63 49 35 36 29 52
Misc. Exp. not W/O
Total Assets 289 329 279 241 249 225 203 188 174 186

Profit Loss View Details >>

Particulars 10 years 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-06 Rs. Cr. TTM
Net Sales 119 166 130 110 60 71 61 86 194 172
Other Income 5 2 2 2 2 2 3 2 2 2
Total Income 124 169 132 112 62 73 65 88 196 174
Total Expenditure -110 -138 -110 -87 -63 -73 -65 -67 -93 -95
PBIDT 14 31 22 25 -1 0 -1 21 103 80
Interest -29 -26 -16 -19 -10 -7 -20 -26 -20 -16
Depreciation -9 -11 -9 -10 -11 -7 -8 -8 -17 -19
Taxation -1 -1 0 2 1 9 -1 4 -21 -19
Exceptional Items 19 2 7 -4 2 -1 -33 -1 -7 -6
PAT -5 -5 4 -7 -19 -6 -63 -10 38 20
Minority Interest -1 0 0 1 2 1 2 -1 1 0
Share Associate
Other Related Items -8
Consolidated Net Profit -14 -5 4 -6 -17 -6 -61 -12 39 20
Adjusted EPS -7 -2 2 -3 -6 -2 -21 -4 14 7

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 11 89 27 12 31 11 27 5 9 79
Cash Fr. Inv. 5 -57 29 17 -13 -3 -4 0 0 -6
Cash Fr. Finan. -13 -26 -60 -30 -19 -10 -23 3 -12 -63
Net Change 3 6 -4 -1 0 -3 -1 9 -3 10
Cash & Cash Eqvt 5 11 7 6 5 2 2 10 7 17

Shareholding Pattern View Details >>

9 Qtrs 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%)
Promoter 19.88 19.88 19.88 19.88 19.88 20.00 20.04 47.79 47.80
Public 80.12 80.12 80.12 80.12 80.12 80.00 79.96 52.21 52.20
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 26.76 26.76 26.76 26.76 26.76 17.95 16.98 7.12 5.53

Announcements View Details >>

Tue, 16 Aug 2022
Amalgamation/Merger
With respect to above we wish to inform you that Lyka Exports Limited a subsidiary, is amalgamating with its holding Company w.e.f. 1st April, 2022 (Appointed Date). We provide following documents for your processing our application for amalgamation viz:1. Scheme of Amalgamation.2. Board Resolutions passed by Board of Directors of Lyka Exports Limited and Lyka Labs Limited approving scheme of amalgamation of Lyka Exports Limited with Lyka Labs Limited. 3. Valuation Report provided by Bhavesh M. Rathod- Registered Valuer.4. Fairness Opinion regarding Valuation of Shares and Exchange Ratio provided by Kunvarji Finstock Private Limited- SEBI Registered Category I Merchant Banker. 5. Audit Committee Report.6. Auditors Certificate under section 133 of the Companies Act, 2013 provided by M/s. D. Kothary & Co, Chartered Accountants, for accounting treatment to be given in the proposed amalgamation separately for Lyka Labs Limited and Lyka Exports Limited.Limited has informed the Exchange about Amalgamation/Merger
Tue, 16 Aug 2022
Reply to Clarification Sought
The Exchange had sought clarification from Lyka Labs Limited with respect to announcement dated 09-08-2022 regarding Appointment.On the basis of aforesaid disclosure, the Listed entity was required to clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer:1. Disclosure of relationships between directors (in case of appointment of a director)2. Brief profile (in case of appointment)3. Confirmation from Director that there are no material reasons for resignation other than that disclosed4. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authorityThe response of the company is attached.
Fri, 12 Aug 2022
Clarification
The Exchange has sought clarification from Lyka Labs Limited with respect to announcement dated 09-Aug-2022 informing about Appointment of Director.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Disclosure of relationships between directors (in case of appointment of a directors) 2. Brief profile (in case of appointment) 3. Confirmation from Director that there are no material reasons for resignation other than that disclosed 4. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.

Technical Scans View Details >>

Tue, 16 Aug 2022
Closing Below Previous Low Closing Below Previous Low
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Decrease 6 Months High Decrease 6 Months
High Increase 1 Year High Increase 1 Year

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,443.18 919.15 +0.5%
Divi's Laboratories Ltd. 99,072.87 3,769.65 +1.0%
Cipla Ltd. 83,487.41 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. 71,536.21 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. 62,537.70 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. 53,261.16 1,563.95 -0.6%
Piramal Enterprises Ltd. 45,983.34 1,974.00 +2.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 56.42 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-06 31.92 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-06 33.44 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 23.91 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 70.76 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 66.33 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-06 24.47 1,974.00 +2.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 4.38 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-06 7.98 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-06 3.87 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 3.53 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 10.52 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 8.31 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-06 1.28 1,974.00 +2.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-03 0.04 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-03 1.56 1,974.00 +2.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-03 3.87 1,974.00 +2.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-03 3.87 1,974.00 +2.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-03 13,993.30 1,974.00 +2.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 919.15 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,769.65 +1.0%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,031.30 -0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,310.65 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,324.70 -0.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,563.95 -0.6%
Piramal Enterprises Ltd. Consolidated 2022-03 1,345.89 1,974.00 +2.4%

FAQ's On Lyka Labs Ltd.

Can I Buy Lyka Labs Shares now?
What is the Share Price of Lyka Labs?
What is the Relative Strength Index (RSI) Value of Lyka Labs?
What is the Market Capital (MCAP) of Lyka Labs?
What are the key metrics to analyse Lyka Labs?
What is the Price Performance of Lyka Labs?